Nifty, Sensex May See Further Consolidation on July 9; Pharma Stocks in Focus

Wednesday, July 9: The Indian stock markets, represented by the Nifty 50 and Sensex, are anticipated to continue their consolidation on July 9, 2025. Investors are exhibiting caution due to a lack of significant fresh catalysts and ongoing global uncertainties.

Range-Bound Sentiment Prevails

As of 8:30 a.m. IST, the GIFT Nifty index was marginally down by 10 points, or 0.04%, trading at 25,587. This suggests a flat-to-negative start for the broader Indian indices. Market participants appear to be holding back, awaiting clearer macroeconomic signals and global developments before taking substantial positions.

On July 8, the markets experienced a late-hour surge, fuelled by renewed optimism surrounding a potential “mini trade deal” between India and the United States. However, this positive sentiment quickly turned cautious after President Donald Trump indicated an imminent announcement regarding pharmaceutical tariffs, potentially reaching as high as 200%.

Pharma Sector in Spotlight

The pharmaceutical sector is expected to be under intense scrutiny today, given these geopolitical developments. Any official announcement of new tariffs by the U.S. could significantly impact market sentiment within this sector. India is the largest overseas market for Indian pharmaceuticals, with exports to the US reaching $9.8 billion in FY25, accounting for 40% of India’s total pharma exports. A 200% tariff could severely affect demand for Indian generics, which play a crucial role in the US healthcare system. While the US has indicated progress toward a new trade agreement with India, the July 9th deadline for suspending reciprocal tariffs (which were paused until August 1st) and Trump’s statements create uncertainty.

Technical Levels to Watch

From a technical perspective, a bullish candle formed on the daily chart, hinting at a potential continuation of the upward trend. For this rally to sustain, the Nifty 50 needs to decisively breach the immediate resistance level at 25,600. A stronger resistance zone is identified near the 25,800 mark.

On the downside, immediate support for the Nifty 50 is located at 25,500, followed by 25,400. A critical support zone is established around the 25,300 level.

Derivatives Data Indicate Key Zones

The India VIX, a measure of market volatility, fell by 2.91% to 12.1950, indicating reduced market apprehension and a relatively stable trading environment.

In the options segment, significant open interest (OI) on the Call side was observed at the 25,600 strike, followed by 25,700, suggesting these levels as potential resistance points. Conversely, on the Put side, the highest OI was concentrated at 25,500 and 25,400, reinforcing these levels as key support zones.

This distribution of open interest highlights that the 25,400–25,600 band will be crucial in determining the Nifty’s immediate directional movement.

Institutional Activity

Provisional data from the NSE indicates that Foreign Portfolio Investors (FPIs) were net sellers on July 8, offloading equities worth ₹26 crore. In contrast, Domestic Institutional Investors (DIIs) were net buyers, injecting ₹1,367 crore into the market on the same day.

What’s Ahead for the Day?

Markets may stay range-bound as consolidation continues amid global uncertainties and a lack of fresh domestic triggers. Pharma stocks will be in focus due to tariff concerns after Trump’s 200% threat on Indian drug exports to the US. Nifty needs to cross 25,600 for further upside, with 25,400–25,600 acting as a key trading range. Lower India VIX suggests limited volatility, while derivatives data hint at cautious positioning. Institutional flow remains mixed, with FPIs selling mildly and DIIs supporting the market.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations